Danaher Corporation

We’re proud to be named a finalist in the 2025 Fierce Life Sciences Innovation Awards for accelerating the real-life impact of gene editing through a personalized #CRISPR therapy platform. This recognition reflects our commitment to solving the hardest problems together—helping innovators compress timelines, scale breakthroughs and improve lives. It’s an honor to be recognized alongside other trailblazers in #lifesciences. 🔗 https://lnkd.in/eAsmT6V2 #FierceLifeSciencesAwards #FierceInnovationAwards

In the latest episode of Behind the Breakthroughs, Danaher's Vanessa Almendro, PhD, MBA recounts how a pioneering team brought bespoke gene editing from concept to clinic—reshaping what’s possible in one-patient medicines and confronting the complex balance of speed, safety and ethics. It's a powerful example of what happens when scientific rigor meets real-world impact, and a must-listen for anyone inspired by the future of precision medicine. 🎧 Listen here: https://bit.ly/4hcz10p

From robotics to digital traceability and cloud scalability, pharma and biotech companies are investing heavily in lab automation. But as Genedata’s Jana Hersch tells Forbes, the biggest returns aren’t just financial—they’re scientific. “While data automation saves money and improves productivity, its most transformative impact lies beyond the experiment," she says. What does that impact look like? Faster, more accurate decisions with less human error that create more capacity for innovation—all outcomes that matter to researchers, clinicians and patients. 🔗 Read more: https://lnkd.in/ezfgN3YN #labautomation #speedoflife

Late nights. Experiments that didn't turn out like you thought they would. Endless iterations. At Danaher, we stand with those who have the audacity to keep going—because we know perseverance is what transforms potential into progress. See how we can help turn persistence into progress: https://bit.ly/4nNxU9Y

14 years ago at the National Cancer Institute (NCI), under the mentorship of Mark Dudley and Steven Rosenberg, I had the humbling privilege of hand-making personalized engineered CAR-T cell therapies for end-stage cancer patients. Today, seven such therapies are FDA-approved and commercially available for blood cancers. Yet despite their curative potential, only 2-4% of US hospitals can access them—limited by labor-intensive, largely manual manufacturing processes, similar to the ones that were used at the NCI. We aim to change that. I’m deeply honored to announce that Cytiva in collaboration with the Innovative Genomics Institute, University of California, San Francisco University of California, Berkeley, Stanford University School of Medicine, The Ohio State University, and fellow Danaher Corporation companies Integrated DNA Technologies and Aldevron has been awarded funding by the Advanced Research Projects Agency for Health (ARPA-H) to develop transformative in vivo CAR-T platform technologies and solutions for solid tumors—innovations that will be made available to drug developers and translational researchers worldwide. The vision: reprogram patients’ immune cells to fight cancer directly in the body using CRISPR gene editing—eliminating costly cell extraction and manufacturing. As Fyodor Urnov beautifully puts it: “We have an Avengers-like team across academia, industry, and government” working to develop a first-in-class injectable gene editor. This remarkable team includes (in alphabetical order): Julia Carnevale, Carlos Castro, Jennifer Doudna , Justin Eyquem, Michael Fischbach, Bridget Keenan, Niren Murthy, David Nguyen, Fyodor Urnov, and Ross Wilson. From hand-crafted therapies to a single, affordable and accessible injection. Read about it here! https://lnkd.in/euY4K7fv https://lnkd.in/e84N2qeW https://lnkd.in/eBwYeenv

Today, we’re proud to announce a new effort to develop a transformative in vivo CAR-T cell therapy platform for gastrointestinal (GI) cancers with a radically reduced manufacturing cost. The project will be funded by the Advanced Research Projects Agency for Health (ARPA-H) Engineering of Immune Cells Inside the Body (EMBODY) program, and undertaken in collaboration with world-leading academic institutions. The collaboration seeks to address three of the most persistent challenges in cell and gene therapy: 1️⃣ Targeting solid tumors: Moving beyond blood cancers to address solid tumors such as gastric, pancreatic and colorectal cancers. 2️⃣ Enabling in vivo CAR-T therapy: Engineering immune cells inside the body to avoid the autologous ex vivo process that drives up complexity and cost. 3️⃣ Achieving significant cost reduction: Making therapies accessible by reducing the cost of manufacturing dramatically by enabling manufacturing at scale. As Dr. Sadik Kassim, Danaher’s Chief Technology Officer for Life Sciences Omics Solutions and the project’s principal investigator, says, “ARPA-H’s investment in EMBODY represents a critical step toward democratizing next-generation immunotherapies.” Read the release: https://lnkd.in/exj2CVRP Cytiva | Integrated DNA Technologies | Aldevron | Innovative Genomics Institute | University of California, San Francisco | University of California, Berkeley | Stanford University School of Medicine | The Ohio State University

“...This isn’t a one-and-done thing. It’s the start of even more testing,” says Adam Clore, Director of Technology R&D at Integrated DNA Technologies. “We’re in something of an arms race.” The pace of innovation in gene editing is staggering. This work, conducted by IDT, Microsoft, and others, reminds us how critical it is to stay ahead of evolving biological threats. Worth a read ⬇️

AI can now design biothreats with the potential to evade current safety controls, raising questions about #biosecurity. A new paper in Science Magazine underscores the urgency—but also proposes solutions built on responsible innovation. We're proud that Integrated DNA Technologies, part of the Danaher ecosystem, made an essential contribution to this work alongside Microsoft and others.   🔗 Read more in MIT Technology Review: https://lnkd.in/gzvy94wE

Exciting progress from our Beacon collaboration with Cincinnati Children's: A new research paper in Advanced Science showcases a powerful platform using liver #organoids to study how medications affect the liver—an essential step in accelerating the development of safe, effective therapies. By enabling earlier identification of unsafe candidates and better alignment on promising ones, this innovation could help save time, resources and lives. Proud to see our Danaher Life Sciences businesses Molecular Devices, Abcam and Leica Microsystems supporting this impactful work. https://bit.ly/4gT83uM Photo: Liver organoid imaged using a Molecular Devices ImageXpress HCS.ai High-Content Screening System with confocal spinning disk at 10X magnification

What do self-driving cars and the #biomanufacturing industry have in common? How do we transition an N-of-1 therapy into N-of-many therapies? And why do the complex new biologics, like ADCs, present unique manufacturing challenges? Beate Dr. Mueller-Tiemann, CTO of Cytiva, and others leading the #Bioprocessing 5.0 revolution answer these questions and more in Genetic Engineering & Biotechnology News: https://lnkd.in/etc6zanp Photo: #Cytiva researchers work on optimizing a range of manufacturing capabilities encompassing monoclonal antibodies, cell and gene therapy, and viral vectors.